Komipharm International Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021
November 12, 2021 at 12:35 pm IST
Share
Komipharm International Co., Ltd. reported earnings results for the third quarter and nine months ended September 30, 2021. For the third quarter, the company reported sales was KRW 220.05 million compared to KRW 162.73 million a year ago. Net loss was KRW 2,437.9 million compared to KRW 973.95 million a year ago. Basic loss per share from continuing operations was KRW 38 compared to KRW 25 a year ago. Diluted loss per share from continuing operations was KRW 38 compared to KRW 25 a year ago. Basic loss per share was KRW 38 compared to KRW 25 a year ago.
For the nine months, sales was KRW 751.8 million compared to KRW 577.69 million a year ago. Net loss was KRW 2,349.2 million compared to KRW 871.39 million a year ago. Basic loss per share from continuing operations was KRW 37 compared to KRW 26 a year ago. Diluted loss per share from continuing operations was KRW 37. Basic loss per share was KRW 37 compared to KRW 26 a year ago.
Komipharm International Co Ltd is a Korea-based company principally engaged in the development and manufacture of veterinary vaccines and veterinary pharmaceuticals. The Companyâs main products include veterinary vaccines such as total vaccines of respiratory disease for swine, vaccines of anthrax disease and black leg for cattle, vaccines for infectious bronchitis and Newcastle disease, and canine respiratory infection killed vaccines, and veterinary pharmaceuticals such as antibiotics, nutrients, disinfectants and others, which are used to treat pneumonia, pasteurellosis, enteritis, mastitis, swine erysipelas, septicemia, leptospirosis and bacterial diseases for livestock. The Company also engages in research and development of anticancer drugs and cancer pain-relieving agents. In addition, the Company provides services such as pathological biopsies, serum tests, and bacteria tests.
KOMIPHARM INTERNATIONAL CO., LTD. 
